The rollator industry is overdue for a transformation, says columnist Dagmar Munn, a longtime user of the device who is living with ALS.
A study is exploring why athletes, first responders, and other high performers face an increased risk of developing ALS.
The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.
A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, aimed at improving access to quality medical ...
Origami is collaborating with Ipsen to develop molecules designed to remove or correct abnormal proteins in neurodegenerative diseases.
Coya Therapeutics raised $11.1 million to support manufacturing scale-up for its experimental ALS therapy, COYA 302.
Watching dancers capture both grief and joy reminded columnist Kristin Neva of her own life as a caregiver to her husband, who has ALS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results